{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.9","value":"5810"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Area under the plasma concentration-time curve from time zero to 12 hours (mass x time x volume-1)","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants in the Pharmacokinetic analysis set (PAS) with an available value for the outcome measure. PAS included all participants who provided at least one evaluable PK concentration of asciminib.","reportingStatus":"POSTED","timeFrame":"Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose","title":"PK Parameter: AUC0-12h for Asciminib","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}